Molecular Templates, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, announced the completion of its previously announced merger with Threshold Pharmaceuticals, Inc., effective as of August 1, 2017. Following the completion of…